(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Jaguar Health, Esports Entertainment Group, and Health Sciences Acquisitions Corporation 2.

The three biggest losers today are Block, Coinbase, and Histogen.

Winners today

1. Jaguar Health (JAGX) – 39.51%

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

NASDAQ ended the session with Jaguar Health jumping 39.51% to $1.13 on Thursday, following the last session’s downward trend. NASDAQ jumped 1.01% to $11,787.40, after three sequential sessions in a row of gains, on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, Jaguar Health has a trailing twelve months EPS of $-53.41.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -433.23%.

Sales Growth

Jaguar Health’s sales growth is negative 3.8% for the ongoing quarter and 48.6% for the next.

More news about Jaguar Health.

2. Esports Entertainment Group (GMBLW) – 34.65%

NASDAQ ended the session with Esports Entertainment Group jumping 34.65% to $0.05 on Thursday, after five sequential sessions in a row of losses. NASDAQ rose 1.01% to $11,787.40, after three sequential sessions in a row of gains, on what was an all-around bullish trend trading session today.

Yearly Top and Bottom Value

Esports Entertainment Group’s stock is valued at $0.05 at 17:32 EST, below its 52-week low of $0.05.

More news about Esports Entertainment Group.

3. Health Sciences Acquisitions Corporation 2 (HSAQ) – 24.16%

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

NASDAQ ended the session with Health Sciences Acquisitions Corporation 2 rising 24.16% to $13.31 on Thursday, after two consecutive sessions in a row of gains. NASDAQ rose 1.01% to $11,787.40, after three sequential sessions in a row of gains, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Health Sciences Acquisitions Corporation 2 has a trailing twelve months EPS of $-0.03.

Yearly Top and Bottom Value

Health Sciences Acquisitions Corporation 2’s stock is valued at $13.31 at 17:32 EST, below its 52-week high of $13.80 and way above its 52-week low of $9.41.

Moving Average

Health Sciences Acquisitions Corporation 2’s value is way above its 50-day moving average of $10.06 and way higher than its 200-day moving average of $9.96.

More news about Health Sciences Acquisitions Corporation 2.

4. Intellicheck (IDN) – 19.51%

Intellicheck, Inc., a technology company, develops, integrates, and markets threat identification and identity authentication solutions for retail and bank fraud prevention, law enforcement threat identification, and mobile and handheld access control and security systems primarily in the United States. The company provides identity systems products, including commercial identification products, such as ID Check SDK for software developers; ID Check – Retail, an identity authentication solution that authenticates identification documents; ID Check – Online that authenticates an on-line user's identification documents; ID Check – Mobile, which provides the fraud reduction benefits of an integrated identity validation system; ID Check – IAM, a software application that speeds up check-in and ID verification within the property management systems; ID Check PC, a standalone software solution, which is designed to provide the features of ID Check for windows based platforms; Age ID, a smartphone or tablet-based solution for preventing sale of age-restricted products to minors; and Defense ID, a mobile and fixed infrastructure solution for threat identification, identity authentication, and access control to military bases, and other government and commercial facilities. It serves government, military, and commercial markets. The company was formerly known as Intellicheck Mobilisa, Inc. and changed its name to Intellicheck, Inc. in May 2017. Intellicheck, Inc. was incorporated in 1994 and is headquartered in Melville, New York.

NASDAQ ended the session with Intellicheck jumping 19.51% to $2.45 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Intellicheck has a trailing twelve months EPS of $0.03.

PE Ratio

Intellicheck has a trailing twelve months price to earnings ratio of 81.67. Meaning, the purchaser of the share is investing $81.67 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.34%.

Moving Average

Intellicheck’s worth is below its 50-day moving average of $2.49 and above its 200-day moving average of $2.35.

Sales Growth

Intellicheck’s sales growth is 17.8% for the current quarter and 22.2% for the next.

Volume

Today’s last reported volume for Intellicheck is 61604 which is 41.03% above its average volume of 43679.

More news about Intellicheck.

5. Riot Blockchain (RIOT) – 17.35%

Riot Platforms, Inc., together with its subsidiaries, focuses on bitcoin mining operations in North America. It operates through Bitcoin Mining, Data Center Hosting, and Electrical Products and Engineering segments. As of December 31, 2021, it operated approximately 30,907 miners. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is headquartered in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 17.35% to $9.51 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-0.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -36.07%.

More news about Riot Blockchain.

6. Inozyme Pharma (INZY) – 14.14%

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Inozyme Pharma jumping 14.14% to $3.39 on Thursday while NASDAQ jumped 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Inozyme Pharma has a trailing twelve months EPS of $-2.26.

Volume

Today’s last reported volume for Inozyme Pharma is 1427700 which is 4.22% below its average volume of 1490740.

Moving Average

Inozyme Pharma’s value is way above its 50-day moving average of $2.52 and way above its 200-day moving average of $2.79.

More news about Inozyme Pharma.

7. 9F (JFU) – 9.88%

9F Inc., together with its subsidiaries, operates a digital financial account platform that integrates and personalizes financial services in the People's Republic of China. Its products include digital financial accounts that offer online lending, online wealth management, and payment facilitation services; revolving and non-revolving loan products to borrowers, as well as traffic referral services to institutional funding partners; and a suite of online wealth management products, such as fixed income products, stocks, insurance, and mutual funds to investors in various platforms, including Wukong Licai, 9F Wallet, and 9F Puhui. The company also provides payment facilitation and other products and services that help users to pay credit card bills and household bills, such as utility bills; and other value-added services, including credit history search, debt consolidation, and user referral services. It has partnerships with borrowers, investors, financial institutions, and merchant partners. The company was formerly known as JIUFU Financial Technology Service Limited and changed its name to 9F Inc. in June 2014. 9F Inc. was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with 9F rising 9.88% to $1.78 on Thursday while NASDAQ jumped 1.01% to $11,787.40.

Earnings Per Share

As for profitability, 9F has a trailing twelve months EPS of $-1.8.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -4.15%.

More news about 9F.

8. Greenpro Capital Corp. (GRNQ) – 9.73%

Greenpro Capital Corp. provides financial consulting and corporate services to small and medium-size businesses primarily in Hong Kong, Malaysia, and China. It operates in two segments, Service Business and Real Estate Business. The company offers business consulting and corporate advisory services, including cross-border listing advisory, tax planning, bookkeeping, advisory and transaction, record management, and accounting outsourcing services; and venture capital related education and support services. It is also involved in the acquisition and rental of real estate properties held for investment and sale; and provision of company formation advisory, company secretarial, and financial services. In addition, the company provides corporate advisory services, such as company review, bank loan advisory, and bank products analysis, as well as loan and credit, and insurance brokerage services; and wealth planning, administration, charity, tax and legal, trusteeship and risk management, investment planning and management, and business support services, as well as asset protection and management, consolidation, and performance monitoring services. The company was formerly known as Greenpro, Inc. and changed its name to Greenpro Capital Corp. in May 2015. Greenpro Capital Corp. was founded in 2013 and is headquartered in Hung Hom, Hong Kong.

NASDAQ ended the session with Greenpro Capital Corp. jumping 9.73% to $1.36 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Greenpro Capital Corp. has a trailing twelve months EPS of $-0.066.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -20.65%.

Yearly Top and Bottom Value

Greenpro Capital Corp.’s stock is valued at $1.36 at 17:32 EST, way below its 52-week high of $5.20 and way above its 52-week low of $1.00.

More news about Greenpro Capital Corp..

9. Netflix (NFLX) – 9.24%

Netflix, Inc. provides entertainment services. It offers TV series, documentaries, feature films, and mobile games across various genres and languages. The company provides members the ability to receive streaming content through a host of internet-connected devices, including TVs, digital video players, television set-top boxes, and mobile devices. The company has approximately 231 million paid members in 190 countries. Netflix, Inc. was incorporated in 1997 and is headquartered in Los Gatos, California.

NASDAQ ended the session with Netflix rising 9.24% to $321.05 on Thursday while NASDAQ rose 1.01% to $11,787.40.

: Netflix stock rallies toward best gain in 5 months, leads S&P 500’s gainersShares of Netflix Inc. powered up 9.1% in midday trading Thursday, enough to pace the S&P 500’s gainers, and putting them on track to close at the highest price for the month.

Netflix (nflx) chooses jon spaihts to pen gears of war movieFor 2023, Netflix expects revenues on a foreign-exchange neutral basis to accelerate during the year.

Netflix (nflx) to launch its swedish original 'one more time'Beside movies or series, Netflix started diversifying its portfolio with its mobile games range, with 40 games to be released this year and 70 games in the development phase., These companies have followed the footsteps of Netflix to compete on a large scale.

Earnings Per Share

As for profitability, Netflix has a trailing twelve months EPS of $8.26.

PE Ratio

Netflix has a trailing twelve months price to earnings ratio of 38.85. Meaning, the purchaser of the share is investing $38.85 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.53%.

Moving Average

Netflix’s worth is below its 50-day moving average of $333.86 and way above its 200-day moving average of $265.33.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Netflix’s stock is considered to be oversold (<=20).

Sales Growth

Netflix’s sales growth is 3.9% for the present quarter and 6.6% for the next.

Previous days news about Netflix

• : Netflix’ stock is still a sell even as ad-supported offering builds an audience, says benchmark. According to MarketWatch on Tuesday, 21 March, "Benchmark reiterated its sell rating on Netflix Inc. stock on Tuesday, and said it remains cautious even after a Sunday report from Bloomberg that the streaming service has gained about 1 million active users of its ad-supported offering after two months on the market. "
• Netflix (nflx) casts gabriel leone as lead of senna miniseries. According to Zacks on Wednesday, 22 March, "Throughout 2023, Netflix expects to see accelerating revenue growth through rolling out paid sharing model in a broad perspective and scaling of lower-priced ad supported plans.", "The series will be produced by Brazil’s Gullane for Netflix with complete support from Senna’s family. "

More news about Netflix.

10. Matterport
(MTTR) – 8.96%

Matterport, Inc., a spatial data company, focuses on digitization and datafication of the built world. It offers Matterport digital twins, a 3D data platform to design, build, operate, promote, and understand spaces. The company offers Matterport Capture, an application that enables to capture depth, data, and imagery of a space using 3D cameras, 360 cameras, and iPhones; Matterport Workshop application to customize, add additional details, and share spaces; Matterport Showcase application for audience view and explore space in its final format; and Matterport VR to experience virtual reality. It offers solutions for real estate, photography, travel and hospitality, retail, insurance and restoration, industrial and facilities management, architecture, and engineering and construction industries. Matterport, Inc. was founded in 2011 and is headquartered in Sunnyvale, California.

NASDAQ ended the session with Matterport
jumping 8.96% to $2.74 on Thursday, after three sequential sessions in a row of losses. NASDAQ jumped 1.01% to $11,787.40, after three successive sessions in a row of gains, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, Matterport
has a trailing twelve months EPS of $-3.367.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.24%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 37.4%, now sitting on 122.07M for the twelve trailing months.

Sales Growth

Matterport
‘s sales growth is 46.6% for the ongoing quarter and 39.3% for the next.

Moving Average

Matterport
‘s worth is way under its 50-day moving average of $3.16 and way under its 200-day moving average of $3.76.

More news about Matterport
.

Losers Today

1. Block (SQ) – -14.74%

Block, Inc., together with its subsidiaries, creates tools that enables sellers to accept card payments and provides reporting and analytics, and next-day settlement. It provides hardware products, including Magstripe reader, which enables swiped transactions of magnetic stripe cards; Contactless and chip reader that accepts Europay, MasterCard, and Visa (EMV) chip cards and Near Field Communication payments; Square Stand, which enables an iPad to be used as a payment terminal or full point of sale solution; Square Register that combines its hardware, point-of-sale software, and payments technology; Square Terminal, a payments device and receipt printer to replace traditional keypad terminals, which accepts tap, dip, and swipe payments. The company also offers various software products, including Square Point of Sale; Square Appointments; Square for Retail; Square for Restaurants; Square Online and Square Online Checkout; Square Invoices; Square Virtual Terminal; Square Team Management; Square Contracts; Square Loyalty, Marketing, and Gift Cards; and Square Dashboard. In addition, it offers a developer platform, which includes application programming interfaces and software development kits. Further, the company provides Cash App, which enables to send, spend, and store money; and Weebly that offers customers website hosting and domain name registration solutions. It serves in the United States, Canada, Japan, Australia, Ireland, France, Spain, and the United Kingdom. The company was formerly known as Square, Inc. and changed its name to Block, Inc. in December 2021. Block, Inc. was incorporated in 2009 and is based in San Francisco, California.

NYSE ended the session with Block falling 14.74% to $61.94 on Thursday, after two consecutive sessions in a row of losses. NYSE dropped 0.33% to $14,693.02, following the last session’s downward trend on what was a somewhat bearish trend exchanging session today.

Stocks making the biggest moves midday: Netflix, block, snap, KB home and moreThe firm alleges that Block facilitates fraud and described the company’s internal systems as a Wild West approach to compliance.

Earnings Per Share

As for profitability, Block has a trailing twelve months EPS of $0.44.

PE Ratio

Block has a trailing twelve months price to earnings ratio of 140.78. Meaning, the purchaser of the share is investing $140.78 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.29%.

Sales Growth

Block’s sales growth is 12.7% for the ongoing quarter and 12.9% for the next.

Volume

Today’s last reported volume for Block is 138106000 which is 1014.73% above its average volume of 12389100.

More news about Block.

2. Coinbase (COIN) – -13.76%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. The company offers the primary financial account in the cryptoeconomy for retailers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable ecosystem partners to build crypto-based applications and securely accept crypto assets as payment. Coinbase Global, Inc. was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase dropping 13.76% to $66.53 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $13.29.

PE Ratio

Coinbase has a trailing twelve months price to earnings ratio of 5. Meaning, the purchaser of the share is investing $5 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.35%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 56.1%, now sitting on 5.04B for the twelve trailing months.

Previous days news about Coinbase

• Coinbase stock down 9% following disclosure of SEC warning. According to MarketWatch on Wednesday, 22 March, "Rest assured, Coinbase products and services continue to operate as usual – today’s news does not require any changes to our current products or services.", "Based on discussions with the SEC, Coinbase said that the potential charges relate to the company’s spot market, its staking service Coinbase Earn, Coinbase Prime and Coinbase Wallet."
• SEC targets coinbase with wells notice and threatens enforcement actions, CEO brian armstrong fights back. According to Benzinga on Wednesday, 22 March, "1/ Today Coinbase received a Wells notice from the SEC focused on staking and asset listings. "

More news about Coinbase.

3. Histogen (HSTO) – -12.59%

Histogen Inc., a clinical-stage therapeutics company, focuses on developing therapeutics based upon the products of fibroblast cells grown under simulated embryonic conditions. It offers HST-001, a hair stimulating complex that is in Phase 1b/2a clinical trial for the treatment of androgenic alopecia (hair loss); HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; and Emricasan, an orally active pan-caspase inhibitor that is in Phase 1 clinical trial for the treatment of COVID-19. The company's pre-clinical programs include HST-004, a cell conditioned media (CCM) solution to treat spinal disc repair; and HST-002, a human-derived collagen and extracellular matrix dermal filler for the treatment of facial folds and wrinkles. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

NASDAQ ended the session with Histogen sliding 12.59% to $1.18 on Thursday while NASDAQ jumped 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Histogen has a trailing twelve months EPS of $-3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -63.43%.

More news about Histogen.

4. Glory Star New Media Group Holdings Limited (GSMGW) – -11.46%

Glory Star New Media Group Holdings Limited provides advertisement and content production services in China. The company also engages in the mobile and online advertising, digital media, and entertainment businesses. In addition, it offers CHEERS app, an e-commerce platform, which provides online store, live streaming, and online games, as well as online short videos, variety shows, and dramas. Glory Star New Media Group Holdings Limited was founded in 2016 and is headquartered in Beijing, China.

NASDAQ ended the session with Glory Star New Media Group Holdings Limited falling 11.46% to $0.01 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Glory Star New Media Group Holdings Limited has a trailing twelve months EPS of $0.54.

PE Ratio

Glory Star New Media Group Holdings Limited has a trailing twelve months price to earnings ratio of 0.02. Meaning, the purchaser of the share is investing $0.02 for every dollar of annual earnings.

Yearly Top and Bottom Value

Glory Star New Media Group Holdings Limited’s stock is valued at $0.01 at 17:32 EST, higher than its 52-week high of $0.01.

More news about Glory Star New Media Group Holdings Limited.

5. Inpixon (INPX) – -10.92%

Inpixon, together with its subsidiaries, provides big data analytics and location based products and related services worldwide. It offers Inpixon Sensor 4000, a passive RF sensor to detect signals ranging from pings to a cell tower to active wireless transmissions; Inpixon IPA Pod offers entry-level barriers to radio detection based indoor positioning; Inpixon Smart School Safety Network solution, a combination of wristbands, ID badges, gateways, and proprietary backend software for school; UWB Sensor Module helps in detection with location; Inpixon GPS 900, a personnel, vehicle, and asset tracking solution; IPA Security, a mobile security and detection product that locates devices operating within a monitored area; Inpixon MDM Connector enables two-way communication between our IPA Security platform and a third-party mobile device management system; Inpixon On-Premises Analytics security customers running systems; and Inpixon GPS Viewer, a browser-based portal used to monitor location and movements of GPS-enabled tracking devices. The company also offers data analytics solutions, such as IPA Wi-Fi, a cloud-based data analytics engine that provides visitor metrics and insights by ingesting diverse data from IoT, third-party, and proprietary sensors; IPA Video analytics to help security personnel combat crime and secure indoor locations; Inpixon Captive Portal, a splash page for their customers to accept terms and conditions before using Wi-Fi; and Shoom Products cloud based applications and analytics for the media and publishing industry. It serves shopping malls, corporate offices, healthcare facilities, government agencies, local publications, and others. The company was formerly known as Sysorex Global and changed its name to Inpixon in March 2017. Inpixon is headquartered in Palo Alto, California.

NASDAQ ended the session with Inpixon sliding 10.92% to $0.35 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Inpixon has a trailing twelve months EPS of $-1.015.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -70.04%.

Volume

Today’s last reported volume for Inpixon is 1098900 which is 65.29% below its average volume of 3166070.

Moving Average

Inpixon ‘s value is way under its 50-day moving average of $1.10 and way under its 200-day moving average of $5.89.

Yearly Top and Bottom Value

Inpixon ‘s stock is valued at $0.35 at 17:32 EST, way under its 52-week high of $24.75 and way higher than its 52-week low of $0.31.

More news about Inpixon .

6. Investcorp Credit Management BDC (ICMB) – -10.55%

CM Finance Inc. is a business development company specializing in loan, mezzanine, middle market, growth capital, and recapitalization investments. The fund typically invests in United States and Europe. Within United States, the fund seeks to invest in Midatlantic, Midwest, Northeast, Southeast, and West Coast regions. The fund primarily invests in cable and satellites; consumer services; healthcare equipment and services; industrials; information technology; telecommunication services; and utilities sectors. The fund seeks to invest in companies with EBITDA more than $15 million. The fund is based in New York, New York.

NASDAQ ended the session with Investcorp Credit Management BDC sliding 10.55% to $3.39 on Thursday, following the last session’s downward trend. NASDAQ jumped 1.01% to $11,787.40, after three sequential sessions in a row of gains, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Investcorp Credit Management BDC has a trailing twelve months EPS of $-0.131.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 0.99%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 2.8%, now sitting on 24.25M for the twelve trailing months.

Moving Average

Investcorp Credit Management BDC’s worth is way under its 50-day moving average of $3.90 and way under its 200-day moving average of $4.07.

Volume

Today’s last reported volume for Investcorp Credit Management BDC is 2229 which is 90.5% below its average volume of 23484.

More news about Investcorp Credit Management BDC.

7. Hycroft Mining Holding Corporation (HYMCW) – -10.26%

Hycroft Mining Holding Corporation, together with its subsidiaries, operates as a gold and silver producer in the United States. The company holds interests in the Hycroft mine covering an area of approximately 70,671 acres located in the state of Nevada. As of December 31, 2020, its Hycroft mine had proven and probable mineral reserves of 11.9 million ounces of gold, and 478.5 million ounces of silver. Hycroft Mining Holding Corporation was formerly known as Mudrick Capital Acquisition Corporation. The company was incorporated in 2017 and is based in Denver, Colorado.

NASDAQ ended the session with Hycroft Mining Holding Corporation falling 10.26% to $0.04 on Thursday, after five consecutive sessions in a row of losses. NASDAQ rose 1.01% to $11,787.40, after three sequential sessions in a row of gains, on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Hycroft Mining Holding Corporation has a trailing twelve months EPS of $-0.965.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -344.81%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 72.4%, now sitting on 45.78M for the twelve trailing months.

More news about Hycroft Mining Holding Corporation.

8. Fulcrum Therapeutics (FULC) – -9.73%

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Fulcrum Therapeutics falling 9.73% to $3.34 on Thursday while NASDAQ rose 1.01% to $11,787.40.

Earnings Per Share

As for profitability, Fulcrum Therapeutics has a trailing twelve months EPS of $-2.62.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -53.53%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Fulcrum Therapeutics’s stock is considered to be overbought (>=80).

More news about Fulcrum Therapeutics.

9. G1 Therapeutics (GTHX) – -9.52%

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer, as well as Phase II clinical trials for the treatment of neoadjuvant breast cancer; lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer; and license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.

NASDAQ ended the session with G1 Therapeutics falling 9.52% to $2.85 on Thursday, following the last session’s downward trend. NASDAQ rose 1.01% to $11,787.40, after three successive sessions in a row of gains, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, G1 Therapeutics has a trailing twelve months EPS of $-3.33.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -139.02%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 76.8%, now sitting on 51.3M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is 44.3% and 42.4%, respectively.

Moving Average

G1 Therapeutics’s worth is way below its 50-day moving average of $5.05 and way under its 200-day moving average of $8.12.

Volume

Today’s last reported volume for G1 Therapeutics is 1694660 which is 30.25% above its average volume of 1301020.

More news about G1 Therapeutics.

10. FuboTV (FUBO) – -9.48%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV dropping 9.48% to $1.05 on Thursday, after two consecutive sessions in a row of losses. NYSE dropped 0.33% to $14,693.02, following the last session’s downward trend on what was a somewhat bearish trend trading session today.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-3.735.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.5%.

Yearly Top and Bottom Value

FuboTV’s stock is valued at $1.05 at 17:32 EST, way under its 52-week low of $1.35.

More news about FuboTV.

Stay up to date with our winners and losers daily report